Does the media prefer ONT or OXB?

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Oxford Biomedica. MarketBeat recorded 7 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.80 beat Oxford Biomedica's score of 0.75 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Nanopore Technologies 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate OXB or SLN?

Oxford Biomedica presently has a consensus price target of GBX 580.85, indicating a potential upside of 30.32%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Biomedica is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate HZD or OXB?

Oxford Biomedica has a consensus target price of GBX 580.85, indicating a potential upside of 30.32%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Does the media prefer PRTC or OXB?

In the previous week, PureTech Health had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for PureTech Health and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.75 beat PureTech Health's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oxford Biomedica (OXB) Competitors

GBX 447 -77.00 (-14.69%)

As of 12:05 PM Eastern

Compare

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

Should you buy Oxford Biomedica stock or one of its competitors? Oxford Biomedica's main competitors and comparable companies include Oxford Nanopore Technologies (ONT), Silence Therapeutics (SLN), Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), and PureTech Health (PRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Oxford Nanopore Technologies presently has a consensus price target of GBX 198.60, indicating a potential upside of 24.28%. Oxford Biomedica has a consensus price target of GBX 580.85, indicating a potential upside of 30.32%. Given Oxford Biomedica's higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -54.66%. Oxford Nanopore Technologies' return on equity of -35.45% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£235M	6.63	-£175.21M	-£15.10	N/A
Oxford Biomedica	£168.74M	3.20	-£143.51M	-£26.92	N/A

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Oxford Biomedica. MarketBeat recorded 7 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.80 beat Oxford Biomedica's score of 0.75 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oxford Nanopore Technologies has a beta of 0.912, indicating that its share price is 9% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

18.3% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Comparatively, 25.8% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Oxford Biomedica (LON:OXB) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Silence Therapeutics has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.20	-£143.51M	-£26.92	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

32.4% of Oxford Biomedica shares are held by institutional investors. 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oxford Biomedica presently has a consensus price target of GBX 580.85, indicating a potential upside of 30.32%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Biomedica is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Biomedica had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Silence Therapeutics. Oxford Biomedica's average media sentiment score of 0.75 beat Silence Therapeutics' score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Biomedica	Positive
Silence Therapeutics	Neutral

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Silence Therapeutics	N/A	N/A	N/A

Summary

Oxford Biomedica beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Avacta Group?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Oxford Biomedica had 1 more articles in the media than Avacta Group. MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Avacta Group. Oxford Biomedica's average media sentiment score of 0.75 beat Avacta Group's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Overall Sentiment
Avacta Group	Neutral
Oxford Biomedica	Positive

Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 46.48%. Oxford Biomedica has a consensus price target of GBX 580.85, indicating a potential upside of 30.32%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

3.1% of Avacta Group shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by company insiders. Comparatively, 25.8% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,802.37	-£30.08M	-£9.66	N/A
Oxford Biomedica	£168.74M	3.20	-£143.51M	-£26.92	N/A

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Summary

Avacta Group and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Horizon Discovery Group plc (HZD.L) has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Oxford Biomedica	£168.74M	3.20	-£143.51M	-£26.92	N/A

32.4% of Oxford Biomedica shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oxford Biomedica had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Horizon Discovery Group plc (HZD.L). Oxford Biomedica's average media sentiment score of 0.75 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Oxford Biomedica	Positive

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Oxford Biomedica has a consensus target price of GBX 580.85, indicating a potential upside of 30.32%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oxford Biomedica beats Horizon Discovery Group plc (HZD.L) on 9 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to PureTech Health?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

PureTech Health has a beta of 0.771, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 321.73%. Oxford Biomedica has a consensus price target of GBX 580.85, suggesting a potential upside of 30.32%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

32.5% of PureTech Health shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Comparatively, 25.8% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.93	-£91.86M	-£46.00	N/A
Oxford Biomedica	£168.74M	3.20	-£143.51M	-£26.92	N/A

In the previous week, PureTech Health had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for PureTech Health and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.75 beat PureTech Health's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PureTech Health and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£539.48M	£3.95B	£7.15B	£2.90B
Dividend Yield	4.57%	3.61%	2.54%	6.17%
P/E Ratio	-16.56	11.84	272.37	367.25
Price / Sales	3.20	1,323.13	618.45	83,663.92
Price / Cash	3.01	44.06	28.78	27.89
Price / Book	6.58	16.86	11.04	6.91
Net Income	-£143.51M	-£22.72M	£3.47B	£5.89B
7 Day Performance	-12.95%	-2.55%	-1.52%	-0.10%
1 Month Performance	-20.41%	11.30%	7.32%	2.87%
1 Year Performance	-22.22%	54.55%	23.96%	21.70%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	2.5899 of 5 stars	GBX 447 -14.7%	GBX 580.85 +29.9%	-7.4%	£541.04M	£168.74M	N/A	891	High Trading Volume
ONT Oxford Nanopore Technologies	2.9276 of 5 stars	GBX 150.56 +7.8%	GBX 193.25 +28.4%	-2.7%	£1.47B	£223.90M	N/A	1,281
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.7645 of 5 stars	GBX 68.50 +3.8%	GBX 99 +44.5%	+12.2%	£320.96M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

How does Oxford Biomedica compare to Avacta Group?

Summary

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Oxford Biomedica compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Do analysts prefer ONT or OXB?

Is ONT or OXB more profitable?

Which has higher valuation and earnings, ONT or OXB?

Does the media prefer ONT or OXB?

Which has more risk and volatility, ONT or OXB?

Do insiders and institutionals believe in ONT or OXB?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Which has stronger valuation and earnings, OXB or SLN?

Do institutionals & insiders have more ownership in OXB or SLN?

Do analysts rate OXB or SLN?

Does the media refer more to OXB or SLN?

Is OXB or SLN more profitable?

Summary

How does Oxford Biomedica compare to Avacta Group?

Does the media favor AVCT or OXB?

Which has more volatility and risk, AVCT or OXB?

Do analysts prefer AVCT or OXB?

Do institutionals and insiders have more ownership in AVCT or OXB?

Which has stronger valuation and earnings, AVCT or OXB?

Is AVCT or OXB more profitable?

Summary

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Which has preferable valuation and earnings, HZD or OXB?

Do institutionals and insiders believe in HZD or OXB?

Does the media prefer HZD or OXB?

Is HZD or OXB more profitable?

Do analysts rate HZD or OXB?

Summary

How does Oxford Biomedica compare to PureTech Health?

Is PRTC or OXB more profitable?

Which has more volatility and risk, PRTC or OXB?

Do analysts recommend PRTC or OXB?

Do institutionals & insiders have more ownership in PRTC or OXB?

Which has stronger earnings & valuation, PRTC or OXB?

Does the media prefer PRTC or OXB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools